Outcomes of Resected Lung Cancer Diagnosed Through Screening and Incidental Pulmonary Nodule Programs in a Mississippi Delta Cohort

IF 3.5 Q2 ONCOLOGY JTO Clinical and Research Reports Pub Date : 2024-08-01 Epub Date: 2024-05-16 DOI:10.1016/j.jtocrr.2024.100684
{"title":"Outcomes of Resected Lung Cancer Diagnosed Through Screening and Incidental Pulmonary Nodule Programs in a Mississippi Delta Cohort","authors":"","doi":"10.1016/j.jtocrr.2024.100684","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Early lung cancer detection programs improve surgical resection rates and survival but may skew toward more indolent cancers.</p></div><div><h3>Methods</h3><p>Hypothesizing that differences in stage-stratified survival indicate differences in biological aggressiveness and possible length-time and overdiagnosis bias, we assessed a cohort who had curative-intent resection, categorized by diagnostic pathways: screening, incidental pulmonary nodule program, and non–program based. Survival was analyzed using Kaplan-Meier plots, log-rank tests, and Cox regression, comparing aggregate and stage-stratified survival across cohorts with Tukey’s method for multiple testing.</p></div><div><h3>Results</h3><p>Of 1588 patients, 111 patients (7%), 357 patients (22.5%), and 1120 patients (70.5%) were diagnosed through screening, pulmonary nodule, and non–program-based pathways; 0% versus 9% versus 6% were older than 80 years (<em>p</em> = 0.0048); 17%, 23%, and 24% had a Charlson Comorbidity score greater than or equal to 2 (<em>p</em> = 0.0143); 7%, 6%, and 9% had lepidic adenocarcinoma; 26%, 31%, and 34% had poorly or undifferentiated tumors (<em>p</em> = 0.1544); and 93%, 87%, and 77% had clinical stage I (<em>p</em> &lt; 0.0001).</p><p>Aggregate 5-year survival was 87%, 72%, and 65% (<em>p</em> = 0.0009), including 95%, 74%, and 74% for pathologic stage I. Adjusted pairwise comparisons showed similar survival in screening and nodule program cohorts (<em>p</em> = 0.9905). Nevertheless, differences were significant between screening and non–program-based cohorts (<em>p</em> = 0.0007, adjusted hazard ratio 0.33 [95% confidence interval: 0.18–0.6]) and between nodule and nonprogram cohorts (adjusted hazard ratio 0.77 [95% confidence interval: 0.61–0.99]). Stage I comparisons yielded <em>p</em> = 0.2256, 0.1131, and 0.911. In respective pathways, 0%, 2%, and 2% of patients with stage I disease who were older than 80 years had a Charlson score greater than or equal to 2 (<em>p</em> = 0.3849).</p></div><div><h3>Conclusions</h3><p>Neither length-time nor overdiagnosis bias was evident in NSCLC diagnosed through screening or incidental pulmonary nodule programs.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 8","pages":"Article 100684"},"PeriodicalIF":3.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000547/pdfft?md5=fe71fffad0f93d3e07e846b753b44c5b&pid=1-s2.0-S2666364324000547-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000547","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Early lung cancer detection programs improve surgical resection rates and survival but may skew toward more indolent cancers.

Methods

Hypothesizing that differences in stage-stratified survival indicate differences in biological aggressiveness and possible length-time and overdiagnosis bias, we assessed a cohort who had curative-intent resection, categorized by diagnostic pathways: screening, incidental pulmonary nodule program, and non–program based. Survival was analyzed using Kaplan-Meier plots, log-rank tests, and Cox regression, comparing aggregate and stage-stratified survival across cohorts with Tukey’s method for multiple testing.

Results

Of 1588 patients, 111 patients (7%), 357 patients (22.5%), and 1120 patients (70.5%) were diagnosed through screening, pulmonary nodule, and non–program-based pathways; 0% versus 9% versus 6% were older than 80 years (p = 0.0048); 17%, 23%, and 24% had a Charlson Comorbidity score greater than or equal to 2 (p = 0.0143); 7%, 6%, and 9% had lepidic adenocarcinoma; 26%, 31%, and 34% had poorly or undifferentiated tumors (p = 0.1544); and 93%, 87%, and 77% had clinical stage I (p < 0.0001).

Aggregate 5-year survival was 87%, 72%, and 65% (p = 0.0009), including 95%, 74%, and 74% for pathologic stage I. Adjusted pairwise comparisons showed similar survival in screening and nodule program cohorts (p = 0.9905). Nevertheless, differences were significant between screening and non–program-based cohorts (p = 0.0007, adjusted hazard ratio 0.33 [95% confidence interval: 0.18–0.6]) and between nodule and nonprogram cohorts (adjusted hazard ratio 0.77 [95% confidence interval: 0.61–0.99]). Stage I comparisons yielded p = 0.2256, 0.1131, and 0.911. In respective pathways, 0%, 2%, and 2% of patients with stage I disease who were older than 80 years had a Charlson score greater than or equal to 2 (p = 0.3849).

Conclusions

Neither length-time nor overdiagnosis bias was evident in NSCLC diagnosed through screening or incidental pulmonary nodule programs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
密西西比三角洲队列中通过筛查和偶然肺结节计划确诊的肺癌切除结果。
方法我们假设分期生存率的差异表明生物学侵袭性的差异以及可能存在的时间长度和过度诊断偏倚,因此我们评估了一组进行了根治性切除术的患者,并按诊断途径进行了分类:筛查、偶然肺结节计划和非计划。我们使用卡普兰-梅耶图、对数秩检验和 Cox 回归分析了生存率,并使用 Tukey's 方法进行多重检验,比较了不同队列的总生存率和分期生存率。0048);17%、23%和24%的患者Charlson合并症评分大于或等于2(P = 0.0143);7%、6%和9%的患者为鳞状腺癌;26%、31%和34%的患者为低分化或未分化肿瘤(P = 0.1544);93%、87%和77%的患者为临床I期(P < 0.0001)。5年总生存率分别为87%、72%和65%(p = 0.0009),其中病理分期I的生存率分别为95%、74%和74%。调整后的配对比较显示,筛查和结节计划队列的生存率相似(p = 0.9905)。然而,筛查队列和非计划队列之间(p = 0.0007,调整后危险比为 0.33 [95% 置信区间:0.18-0.6])以及结节队列和非计划队列之间(调整后危险比为 0.77 [95% 置信区间:0.61-0.99])存在显著差异。I 期比较得出的 p = 0.2256、0.1131 和 0.911。结论在通过筛查或偶然肺结节项目确诊的 NSCLC 患者中,时长偏差和过度诊断偏差均不明显。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
期刊最新文献
Corrigendum to ‘First Central Asian Forum on Lung Cancer’ [JTO Clinical and Research Reports Volume 7 Issue 1 (2026) 100898] Pulmonary Malignancies in Adults With Congenital Lung Malformations: A Scoping Review Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1